MedPath

A Study On The Effectiveness Of Pippalyadi Churna In Treating Yeast Infection.

Phase 2/3
Not yet recruiting
Conditions
Vaginitis, vulvitis and vulvovaginitis in diseases classified elsewhere. Ayurveda Condition: KAPAJA-YONIROGAH,
Registration Number
CTRI/2025/03/083397
Lead Sponsor
Dr Prerna
Brief Summary

Ayurvedic texts outline 20 specificgynecological disorders, each with its own unique characteristics andimplications. Kaphaja Yonivyapad is one among most frequently seen conditionsout of these.It presents in the form of Pichhila(sliminess), Sheeta (cold), Panduvarna *(*white colored) andKanduyukta srava (discharge with itching*),* Alpa Vedana (mild pain) of yoni. The sign and symptoms of Kaphaja Yoni Vyapad are correlated withCandidiasis because the the description and characteristic features of thedisease have coincided with the description of Candidiasis more than any othertype of Yoniroga*.* Vulvovaginal Candidiasis is the infection of thegenital region which causes irritation, burning sensation, discharge (similarto white cottage cheese) and intense itching of the vagina and the vulva — thetissues at the vaginal opening. Yonibeing a direct route to Garbhashaya(uterus), if diseased can affectentire Kshetra needed for growing embryo and its development. Hence it isimportant to address this problem so that women can live a healthy life.Present study is undertaken with a purpose to identify the effect of PippalyadiChurna in the management of Kaphaja Yonivyapad w.s.r. to VulvovaginalCandidiasis.Acharya Charaka mentioned use of this drug in yonisravaunderKaphaja Yonivyapad Chikitsa in chapter 30 of chikitsa sthan.

At first, all participants will bescreened to check their eligibility for the study. A total of 30 clinicallydiagnosed patients will be enrolled in this study after taking informed writtenconsent. After that, the first assessment will be done before drugadministration with a validated questionnaire and grading will be doneaccording to the signs and symptoms of the patients. Then the drug therapy willbe started and the total duration will be 30 days. Three follow ups will bedone each after 10 days. The last assessment will be done on the 30th day andthe grading will be given again to see the changes in the signs and symptoms ofkaphaja yonivyapad. Signatures on informed consent and patient informationsheets will be taken on hard copy, and all other relevant data for the studywill be collected. After the collection of all the relevant data, the analysisof the data will be done.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • 1.Enrolled patients with consent form.
  • 2.Patient complaining of any two from Yoni Srava (Vaginal Discharge) Yoni Pichhilta(Vaginal Sliminess) yoni Kandu (Itching) Alpa Vedana (Mild Pain) •Yoni Shitalta (Vaginal Coldness) 3.Microscopically positive for Pseudohyphae.
  • 4.Women suffering from recurrent VVC.
Exclusion Criteria
  • 1.Patients not willing to participate in the trial.
  • 2.Unmarried women 3.Age less than18 or more than 40 years 4.Pregnant females and lactating mothers.
  • 5.known cases of HTN, DM, Hypo and hyperthyroidism, TB.
  • 6.Diagnosed patients of HIV, VDRL, HBsAg 7.Women with PID and cervical intraepithelial neoplastic lesions.
  • 8.Women taking oral contraceptive pills.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in signs and symptoms of kapahaja yonivyapad1st,10th,20th, 30th day
Secondary Outcome Measures
NameTimeMethod
1.Improvement in quality of life2.Prevention of recurrence

Trial Locations

Locations (1)

Kunwar Shekhar Vijendra Ayurved Medical Hospital And Research Center Gangoh Saharanpur-247341

🇮🇳

Saharanpur, UTTAR PRADESH, India

Kunwar Shekhar Vijendra Ayurved Medical Hospital And Research Center Gangoh Saharanpur-247341
🇮🇳Saharanpur, UTTAR PRADESH, India
Dr Prerna
Principal investigator
7082152836
prernasaini0001@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.